You are here

  • Home
  • Archive
  • Volume 67, Issue 11
  • Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk
  1. Hidekazu Suzuki1,
  2. Juntaro Matsuzaki2
  1. 1 Fellowship Training Center, Medical Education Center, Keio University School of Medicine, Tokyo, Japan
  2. 2 Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan
  1. Correspondence to Professor Hidekazu Suzuki, Fellowship Training Center, Medical Education Center, Keio University School of Medicine, Tokyo 160-8582, Japan; hsuzuki.a6{at}keio.jp

https://doi.org/10.1136/gutjnl-2017-315698

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The current guidelines recommend that when patients require long-term use of proton pump inhibitors (PPIs), Helicobacter pylori (H. pylori) should be eradicated beforehand because it improves atrophic gastritis, a precancerous lesion.1 2 The recent analysis by Cheung et al 3 of the data of more than 60 000 adults registered in a territory-wide health database in Hong Kong who underwent H. pylori eradication showed that the long-term use of PPIs increased the risk of gastric cancer by 2.4-fold. Moreover, the risk of gastric cancer increased with the dose and duration of PPI use. The fact that long-term PPI administration increases the risk of gastric cancer even after H. pylori eradication is unexpected. …

    View Full Text

    Footnotes

    • Competing interests The authors received scholarship funds for the research from Daiichi-Sankyo, Co., EA Pharm. Co., Otsuka Pharma Co., Tsumura Co. and received service honoraria from Astellas Pharma, Co., AstraZeneca KK, EA Pharma Co., Mylan EPD, Co., Otsuka Pharm. Co., Takeda Pharm Co., Ltd., and Tsumura, Co.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles